TR201902755T4 - Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari. - Google Patents

Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari. Download PDF

Info

Publication number
TR201902755T4
TR201902755T4 TR2019/02755T TR201902755T TR201902755T4 TR 201902755 T4 TR201902755 T4 TR 201902755T4 TR 2019/02755 T TR2019/02755 T TR 2019/02755T TR 201902755 T TR201902755 T TR 201902755T TR 201902755 T4 TR201902755 T4 TR 201902755T4
Authority
TR
Turkey
Prior art keywords
formulations
tripeptide
lyophilized
storage stability
lyophilized formulations
Prior art date
Application number
TR2019/02755T
Other languages
English (en)
Inventor
Abels Christoph
CHRISTIANS Thorsten
Knie Ulrich
Original Assignee
Dr August Wolff Gmbh & Co Kg Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr August Wolff Gmbh & Co Kg Arzneimittel filed Critical Dr August Wolff Gmbh & Co Kg Arzneimittel
Publication of TR201902755T4 publication Critical patent/TR201902755T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use

Abstract

Buluş, bir Lizil-Prolil-Treonin formülasyonları ile, hususi olarak da depolama kararlılığına sahip L-Lizil-D-Prolil-L-Treonin liyofilize formülasyonlar ile ve liyofilize formülasyonlar hazırlamak için bir proses ile ilgilidir. Bundan başka, buluş, bir memelide ağrı-ilişkili hastalıkların, pruritus-ilişkili hastalıkların, inflamatuar hastalıkların ve/veya başka hastalıkların terapötik ve/veya profilaktik tedavi, tanılama ve/veya terapisinde kullanılan liyofilize formülasyonlar içeren farmasötik ve kozmetik kompozisyonlar ile ilgilidir.
TR2019/02755T 2013-11-07 2014-10-27 Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari. TR201902755T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13191934 2013-11-07

Publications (1)

Publication Number Publication Date
TR201902755T4 true TR201902755T4 (tr) 2019-03-21

Family

ID=49551529

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02755T TR201902755T4 (tr) 2013-11-07 2014-10-27 Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari.

Country Status (18)

Country Link
US (1) US10383911B2 (tr)
EP (1) EP3065756B1 (tr)
JP (1) JP6475714B2 (tr)
KR (1) KR20160072266A (tr)
CN (1) CN105744945B (tr)
AU (1) AU2014345802B2 (tr)
CA (1) CA2927690C (tr)
DK (1) DK3065756T3 (tr)
ES (1) ES2727324T3 (tr)
HK (1) HK1222801A1 (tr)
HU (1) HUE043367T2 (tr)
MX (1) MX368943B (tr)
NZ (1) NZ719321A (tr)
PL (1) PL3065756T3 (tr)
RU (1) RU2684915C2 (tr)
SG (1) SG11201603440SA (tr)
TR (1) TR201902755T4 (tr)
WO (1) WO2015067493A1 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111035764B (zh) * 2018-10-14 2021-09-07 深圳市健元医药科技有限公司 一种治疗类风湿性关节炎的组合物及其制备方法
CN111150831B (zh) * 2020-02-27 2023-06-09 广州领晟医疗科技有限公司 多肽KdPT的应用
CN111303242B (zh) * 2020-02-27 2022-04-26 广州领晟医疗科技有限公司 一种KdPT的修饰肽
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US65857A (en) * 1867-06-18 Joseph bell alexander
ATE125548T1 (de) 1988-03-28 1995-08-15 British Tech Group Peptide.
US20090011819A9 (en) * 2000-10-20 2009-01-08 Marcel Huard Method and apparatus for the rewarding of the interest of a user in an activity
DE10106852A1 (de) * 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
AU2006210895A1 (en) * 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic PHSCN-peptide
KR20080033939A (ko) * 2005-06-17 2008-04-17 리지너크스 바이오 파마소티컬스, 인코포레이티드 동결 건조된 형태이거나, 또는 동결 건조될 수 있는 형태인엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
JP2010538984A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｒｇｄ−ペプチドおよび／または副甲状腺ホルモン（１−３４）の抗ｈｉｖ剤としての使用
CA2703891A1 (en) * 2007-11-19 2009-05-28 Universitaetsklinikum Muenster Compositions for reducing oxidative stress and uses thereof
WO2009082648A1 (en) * 2007-12-21 2009-07-02 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
NZ600271A (en) 2009-11-24 2013-09-27 Grifols Therapeutics Inc Lyophilization methods, compositions, and kits
EP2758066A1 (en) * 2011-09-23 2014-07-30 Westfälische Wilhelms-Universität Münster Tripeptide kdpt for antiapoptotic treatment

Also Published As

Publication number Publication date
CA2927690A1 (en) 2015-05-14
WO2015067493A1 (en) 2015-05-14
PL3065756T3 (pl) 2019-07-31
JP6475714B2 (ja) 2019-02-27
JP2016535747A (ja) 2016-11-17
CA2927690C (en) 2020-10-27
EP3065756B1 (en) 2019-02-20
ES2727324T3 (es) 2019-10-15
RU2016121401A (ru) 2017-12-12
US10383911B2 (en) 2019-08-20
MX368943B (es) 2019-10-22
US20160279188A1 (en) 2016-09-29
CN105744945B (zh) 2019-07-02
CN105744945A (zh) 2016-07-06
AU2014345802B2 (en) 2018-01-25
SG11201603440SA (en) 2016-05-30
RU2684915C2 (ru) 2019-04-16
HUE043367T2 (hu) 2019-08-28
EP3065756A1 (en) 2016-09-14
MX2016005976A (es) 2016-08-11
AU2014345802A1 (en) 2016-05-12
HK1222801A1 (zh) 2017-07-14
DK3065756T3 (da) 2019-05-27
NZ719321A (en) 2020-06-26
KR20160072266A (ko) 2016-06-22

Similar Documents

Publication Publication Date Title
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
IN2014DN10386A (tr)
TR201905586T4 (tr) Amorf dapagli̇flozi̇n i̇çeren formülasyonlar
EA201370018A1 (ru) Составы рифаксимина и их применение
MX2013004061A (es) Analogos de ciclosporina.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
WO2014210037A3 (en) A composition of mesenchymal stem cells
EA201590491A1 (ru) Иммуногенная композиция
MX2013004062A (es) Analogos de ciclosporina.
EA201391440A1 (ru) Производные пиразолопиримидина
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
TR201902755T4 (tr) Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari.
UY33219A (es) Cetoenoles cíclicos para terapias
IN2014DN09437A (tr)
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.